Kai Pinkernell

Kai Pinkernell

Company: Glycostem Therapeutics B.V.

Job title: CMO


Bringing Allogeneic NK cells into Clinical Trials for AML 2:30 pm

Providing an update on oNKord®, an allogeneic NK cell product, in the WiNK AML trial Understanding the safety aspects of the clinical trial for the use of allogeneic NK cells Understanding the role of conditioning chemotherapy for therapeutic efficacyRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.